SIGA Technologies Inc
NASDAQ:SIGA

Watchlist Manager
SIGA Technologies Inc Logo
SIGA Technologies Inc
NASDAQ:SIGA
Watchlist
Price: 6.28 USD -0.16%
Market Cap: 448.2m USD
Have any thoughts about
SIGA Technologies Inc?
Write Note

SIGA Technologies Inc
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

SIGA Technologies Inc
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
SIGA Technologies Inc
NASDAQ:SIGA
Total Current Liabilities
$22.3m
CAGR 3-Years
6%
CAGR 5-Years
14%
CAGR 10-Years
17%
Johnson & Johnson
NYSE:JNJ
Total Current Liabilities
$51.8B
CAGR 3-Years
5%
CAGR 5-Years
8%
CAGR 10-Years
8%
Bristol-Myers Squibb Co
NYSE:BMY
Total Current Liabilities
$22.6B
CAGR 3-Years
2%
CAGR 5-Years
17%
CAGR 10-Years
11%
Pfizer Inc
NYSE:PFE
Total Current Liabilities
$43.8B
CAGR 3-Years
2%
CAGR 5-Years
3%
CAGR 10-Years
8%
Merck & Co Inc
NYSE:MRK
Total Current Liabilities
$29.6B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
1%
Eli Lilly and Co
NYSE:LLY
Total Current Liabilities
$24.7B
CAGR 3-Years
22%
CAGR 5-Years
18%
CAGR 10-Years
13%
No Stocks Found

SIGA Technologies Inc
Glance View

Market Cap
448.2m USD
Industry
Pharmaceuticals

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The company is headquartered in New York City, New York and currently employs 39 full-time employees. The Company’s lead product, TPOXX (oral TPOXX), is an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The firm does not have a manufacturing infrastructure and does not intend to develop one for the manufacture of TPOXX. The company uses contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture TPOXX. The Company’s CMOs apply methods and controls in facilities, which are uses for manufacturing, processing, packaging, testing, analyzing and holding pharmaceuticals, which conform to current good manufacturing practices (cGMP), the standard set by the FDA for manufacture and storage of pharmaceuticals intended for human use. For the manufacture of oral TPOXX, the Company uses the four CMOs, namely W.R. Grace and Company; Powdersize, LLC; Catalent Pharma Solutions LLC, and Packaging Coordinators, LLC.

SIGA Intrinsic Value
13.67 USD
Undervaluation 54%
Intrinsic Value
Price

See Also

What is SIGA Technologies Inc's Total Current Liabilities?
Total Current Liabilities
22.3m USD

Based on the financial report for Sep 30, 2024, SIGA Technologies Inc's Total Current Liabilities amounts to 22.3m USD.

What is SIGA Technologies Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
17%

Over the last year, the Total Current Liabilities growth was -27%. The average annual Total Current Liabilities growth rates for SIGA Technologies Inc have been 6% over the past three years , 14% over the past five years , and 17% over the past ten years .

Back to Top